Table 3

The efficacy of H. pylori eradication or screen-and-eradication strategy in the risk reduction of gastric cancer: ongoing trials

Country registration numberSubjects/designExperiment groupControl groupPrimary outcomeAge (years)Sample size/statusStart year/expected completion year
Effectiveness of H. pylori eradication
 China/ChiCTR-TRC-10000979Healthy subjects/double blindBismuth quadruple therapyBismuth + omeprazole + placeboGastric cancer incidence25–5494 101/recruitment completed2011–2013/NA
 Korea/NCT02112214Healthy H. pylori infected subjects/double blindBismuth quadruple therapyPlaceboGastric cancer incidence40–605224/recruitment completed2014/2029
 UK/NCT01506986 H. pylori-infected aspirin user/double blindTriple therapyPlaceboPeptic ulcer bleeding≥603038/recruitment completed2012/2021
Effectiveness of screening and eradication of H. pylori
 UK/ISRCTN71557037Healthy subjects/open label H. pylori screeningNo screeningGastric cancer incidence and mortalityM: 35–69; F:45–6956 000/recruitment completed1997/2021
 Taiwan/NCT01741363Healthy subjects/open label H. pylori screening and FITFIT aloneGastric cancer incidence50–6960 000/recruitment completed2014/2017
 Latvia/NCT02047994Healthy subjects/open label H. pylori screening and FITFIT aloneGastric cancer mortality40–6430 000/recruiting2013/2033
  • FIT, faecal immunochemical test; NA, not available.